Abbvie (ABBV) stock
Last close $286.20 on 2026-11-20 (+0.94%) · Sector: Healthcare
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois, that researches, develops, and sells prescription medicines. It makes most of its money by selling these drugs to patients, doctors, hospitals, and pharmacies around the world.
AbbVie's revenue and profit have grown strongly in recent quarters, with trailing revenue of $66.0 billion and revenue growth of 10.7%. Over the past year the stock returned 21.1%, beating the S&P 500's 4.7% gain, and it trades 2.6% above its 50-day average and 18.0% above its 200-day average. Insiders sold about $11.9 million of stock in the last 90 days and made no purchases, and the stock has moved both up and down after past earnings reports.
Key numbers
- Market cap: $507.1B
- Revenue (last 12 months): $66.01B
- Revenue growth: +10.7%
- Gross margin: 73.7%
- Operating margin: 32.2%
- P/E: 49.3
- P/S: 7.7
- Current ratio: 0.87
Quality score
Overall 41/100 · growth 39 · profitability 59 · financial health 67 · value 0
Performance and risk
1-year return +21.1% vs S&P 500 +4.7% · volatility 25.2% (S&P 500 14.3%) · largest drop -16.5% · beta -0.04
Stock move the day after earnings
- 2026-01-07: -4.0%
- 2026-02-04: -3.8%
- 2026-04-03: -1.0%
- 2026-04-29: +3.1%
- 2026-07-06: -0.0%
- 2026-07-31: -2.5%
- 2026-10-05: +0.3%
- 2026-10-30: +1.4%
Congress trades (90 days)
0 buys, 1 sells
Insider trades (12 months)
Bought $0.0M · sold $30.8M
ABBV stock research · ABBV options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.